Monograph
J01DD13 - Cefpodoxime |
Propably not porphyrinogenic |
PNP |
Rationale
The proxetil ester gives rise to cefpodoxime, which is in greater parts excreted in unchanged form No data pointing to CYP-interaction. Conflicting references.
Chemical description
Perorally administered betalactamase stable cephalosporin administered as proxetil ester, used (up to 200 mg x 2) in acute sinusitis, acute otitis media and pharyngotonsillitis where penicillins are ineffective. Hydrolyzed in the intestine to cefpodoxim which is absorbed systematically. 80% is excreted in unchanged form in urine. No data pointing to CYP induction. French list: unsafe South African list: use with caution Cefalosporins: Metabolic Basis…. ref 383: potentially unsafe.
IPNet drug reports
Uneventful use reported in 2 patients with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
United Kingdom
Serbia© NAPOS 2024